Insightec Hits 10,000 EMEA Patients Treated With Focused Ultrasound
Haifa/Frankfurt – September 11, 2026 -- Insightec has treated 10,000 patients across Europe, the Middle East and Africa with its Exablate Neuro platform for essential tremor and Parkinson's disease, a figure that has more than doubled over the past three years. The incisionless MR-guided focused ultrasound (MRgFUS) therapy is now available at more than 62 treatment centers in 20 countries across the region, part of a global network exceeding 30,000 patients treated at 226 centers worldwide.
Treatment volumes double in three years as adoption accelerates
The EMEA milestone caps a decade of expansion for focused ultrasound in the region, with hospitals increasingly offering the incisionless approach to patients whose only prior options were medication or invasive surgery. Growth spans both essential tremor and Parkinson's disease indications, according to Jake Ghannam, Executive Vice President and Chief Commercial Officer at Insightec.